Welcome to our dedicated page for iRhythm Holdings SEC filings (Ticker: IRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The iRhythm Technologies, Inc. (NASDAQ: IRTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a public issuer. As a digital health care company focused on ambulatory cardiac monitoring and data analytics, iRhythm uses its SEC reports to communicate financial performance, risk factors, governance matters, and material corporate events related to its Zio long-term continuous monitoring (LTCM) service and broader operations.
Investors can use this page to review current and historical filings retrieved from the SEC’s EDGAR system, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. Recent 8-K filings have covered topics such as quarterly financial results, investor presentations, and amendments to the Executive Change in Control and Severance Policy, which outlines severance payments, COBRA coverage, and equity vesting treatment for senior leaders under specified termination scenarios.
For those analyzing iRhythm’s business in more depth, the company’s periodic reports typically discuss revenue from Zio services, gross margins, operating expenses, non-GAAP measures like adjusted EBITDA and adjusted net loss, and liquidity metrics such as cash, cash equivalents, and marketable securities. These documents also describe how iRhythm accounts for items like stock-based compensation, business transformation costs, and other adjustments that affect non-GAAP results.
Stock Titan enhances access to these filings with AI-powered summaries that help explain the key points of lengthy documents, such as 10-K and 10-Q reports, in more accessible language. Users can quickly identify major changes in financial condition, updates to risk disclosures, and details of insider or executive-related arrangements that appear in forms and exhibits. This combination of real-time filing access and AI-generated insights can support investors, analysts, and other stakeholders who want to understand how iRhythm reports on its digital cardiac monitoring business and corporate governance over time.
iRhythm Holdings, Inc. executive vice president Mervin Smith reported performance-based equity vesting and related tax sales of company stock. He acquired 9,210 shares of common stock on February 24, 2026 at $0.00 per share from performance RSUs after a board committee determined the performance conditions were met.
On February 25, 2026, he sold 4,041 shares of common stock at an average price of $135.4189 per share to cover tax withholding and remittance obligations tied to the RSU vesting. After these transactions, he directly owned 20,275 shares of iRhythm common stock.
iRhythm Holdings EVP and Chief Risk Officer Sumi Shrishrimal reported equity compensation activity and a related tax sale. On February 24, 2026, she acquired 11,294 shares of common stock at $0.00 per share from performance RSUs granted on February 27, 2023, after the board committee determined performance conditions were met. This increased her direct holdings to 45,399 shares. On February 25, 2026, she sold 6,217 shares of common stock at an average price of $135.4189 per share, leaving 39,182 shares held directly. A footnote states these shares were sold to cover tax withholding and remittance obligations tied to the vesting of the performance RSUs.
iRhythm Holdings, Inc. Chief Accounting Officer Marc Wade Rosenbaum reported two transactions in common stock. On February 24, 2026, he acquired 9,210 shares at $0.00 per share through a grant determined by the board’s Compensation & Human Capital Management Committee after performance conditions for previously granted performance RSUs were met. On February 25, 2026, he sold 4,797 shares at an average price of $135.4189 per share to cover tax withholding and remittance obligations related to the vesting of those performance RSUs. Following these transactions, he directly owned 15,014 shares of iRhythm common stock.
iRhythm Holdings executive Chad Patterson reported a mix of stock transactions. On February 24, 2026, he acquired 17,318 shares of common stock at $0.00 per share through the vesting of performance RSUs, after the board’s Compensation & Human Capital Management Committee determined performance conditions for RSUs granted on February 27, 2023 were met. On February 25, 2026, he sold 8,967 shares of common stock at an average price of $135.4189 per share to cover tax withholding and remittance obligations related to that vesting. Following these transactions, he directly owned 51,738 shares of iRhythm common stock.
iRhythm Holdings, Inc. executive Patrick Michael Murphy, the company’s CBO and CLO, acquired 15,060 shares of common stock on a grant/award basis after performance conditions were met for previously granted performance RSUs. On the following day, he sold 7,805 shares in open-market transactions at an average price of $135.4189 per share to cover tax withholding and remittance obligations related to the vesting. After these transactions, he directly owned 60,536 shares of iRhythm common stock.
iRhythm Holdings President and CEO Quentin S. Blackford reported a performance-based stock vesting and related tax sale. On February 24, he acquired 46,687 shares of common stock at no cost through the vesting of performance RSUs granted on February 27, 2023, after the board committee determined the performance conditions were met.
On February 25, he sold 25,540 shares of common stock at an average price of $135.4189 per share solely to cover tax withholding and remittance obligations tied to that vesting. After these transactions, he directly owned 186,126 shares of iRhythm common stock.
iRhythm Holdings, Inc. Chief Accounting Officer Marc Wade Rosenbaum reported an open-market sale of 280 shares of common stock at an average price of $140.91 per share on February 24, 2026. After this sale, he directly holds 10,601 shares of iRhythm common stock.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan that he established on May 12, 2025 and modified on November 25, 2025, which is designed to allow systematic share sales according to preset instructions.
iRhythm Holdings, Inc. executive vice president of strategic business operations Mervin Smith reported an open-market sale of common stock. On February 24, 2026, he sold 732 shares at an average price of $140.91 per share.
After this transaction, Smith directly owned 15,106 shares of iRhythm common stock. The sale was executed under a pre-established Rule 10b5-1 trading plan that Smith adopted on November 19, 2025, indicating the trades were made according to a predetermined schedule.
iRhythm Holdings, Inc. director Abhijit Y. Talwalkar reported exercising employee stock options for 5,312 shares at $10.710 per share and receiving an equal number of common shares on February 23, 2026. He then sold 5,312 common shares in multiple open-market transactions at prices including $143.400, $145.317, $146.951, and $147.616 per share, leaving 20,299 shares of common stock held directly.
All transactions were carried out under a Rule 10b5-1 trading plan established on May 12, 2025. The exercised option was originally granted on May 23, 2016 for 21,248 shares, vested in thirty-six equal monthly installments, and has an expiration date of May 23, 2026; the plan covers options expiring in 2026 and 2027.